Latest Press Release

MEC Announces Submission Of Listing Statement To The CSE In Coordination With Albert Labs RTO

Albert Labs -

Accelerating access to psychedelics-based medicines for patients with urgent and unmet needs

1906 to 2020, from Albert Hofmann's birth to ours >>

Rethinking the clinical trial paradigm.

We’re different. We focus on Real World Data to meet immediate, unmet, clinical needs.

Continued success shows psychedelic medicine is a potential game-changer, but patients could be waiting 5+ years for new treatments to come to market.

Portable, scalable strategy for revenue growth.

Albert Labs is a catalyst leading a collaboration with academic institutions, hospital networks and existing reimbursement mechanisms.

Leveraging existing clinic & research infrastructure.
Academic partnerships drive next gen psychedelic R&D.
Preidenitfied, accessible patient pools.
Proprietary Real World Data to gain early reimbursement.
In-house lab results in formulation & delivery IP.

Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Let us tell you more.

We will email you to start the conversation.

Meet the experts delivering real world evidence to enable access to psychedelic medicine to those most in need.

Albert has the people, expertise, and connections to build these unique protocols. Albert's team have delivered successful trials across multiple compounds, conditions and jurisdictions within Europe.

"There is an opportunity here to provide something of real value to patients who are truly suffering."

"The average clinical trial takes 6-12 years and costs over half a billion dollars we can't let patients wait that long."

UK focus, supplied by Canadian R&D facility.

Application has been made for a dealers license allowing Albert Labs to test, possess, import and export. Proprietary bioreactor cultivation, extraction and formulation protocols using Industry-leading technology.

Faster

Through Real World Evidence we can accelerate innovation and access to patients suffering now and generate revenue along the way.

Focused

Patient focused data and physician usage experience will help unlock reimbursement pathways faster bringing science and continuity to those in need.

Credible

Real World Evidence is quickly becoming the acceptable protocol to assess innovative formulations as effective. Regarded by regulators and policymakers.

Insights

Larger data sets from a breadth of representative patient populations. Real-world insights enable us to develop unique formulations and delivery

<<1906 from Albert Hofmann's birth to ours

Standing on the shoulders of the giants that went before.

We are driven to develop the vision of those that revealed the true power of psychedelics as medicines.

“The outcome of these experiments took place in the framework of systematic pharmaceutical, chemical research.”

- Albert Hofmann, 1938 Novartis Labs (Sandoz) , Basel Switzerland.

Who is Albert?

Albert Hofmann pioneered the discovery and development of psychedelic therapies including LSD & Psilocybin, understanding their therapeutic value first hand.

Let us tell you more.

We will email you to start the conversation.